Study of AK156 in Primary Osteoporosis Patients

NCT01522521 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

600

Enrollment

INDUSTRY

Sponsor class

Conditions

Osteoporosis

Interventions

DRUG: AK156
DRUG: Placebo

Sponsor

Asahi Kasei Therapeutics Corporation